Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of evinacumab in persistent hypercholesterolemia despite maximally tolerated lipid-modifying therapy
2017-001508-31Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia and familial hypercholesterolemia (FH) comparing Evinacumab varying dose regimens with Placebo (2 arms). Started Aug 2017; status: completed.
02
Drugs
evinacumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2017-001508-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001508-31.